Quick Answer
Immunovant, Inc. reported R&D Expense of $101.81 million for fiscal year 2022.
Immunovant, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2022 | $101.81M | +48.4% |
| 2021 | $68.60M | +43.1% |
| 2020 | $47.93M | +86.2% |
| 2019 | $25.73M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $37.74M | +76.7% | +32.7% |
| June 30, 2022 | $28.43M | +52.0% | -4.5% |
| December 31, 2021 | $29.76M | +41.1% | +39.3% |
| September 30, 2021 | $21.36M | +78.4% | +14.2% |
| June 30, 2021 | $18.70M | +10.5% | -11.3% |
| December 31, 2020 | $21.09M | +325.8% | +76.1% |
| September 30, 2020 | $11.98M | +15.9% | -29.2% |
| June 30, 2020 | $16.92M | -8.4% | +241.7% |
- Immunovant, Inc. showed an increase of +48.4% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2022 period, Immunovant, Inc.’s r&d expense has grown by 295.6% (from $25.73 million to $101.81 million).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on June 8, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: